Lymphoma, Large B-Cell, Diffuse: all 1,432 studies

Page 2 of 15. Open to participants first (359), then studies with results posted, then the rest; newest registration first within each.

• Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCLRecruitingNCT07012980Phase 2
• A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell LymphomaRecruitingNCT07011056Phase 3
• Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous TransplantationRecruitingNCT07001540Phase 2
• Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)RecruitingNCT06977711Phase 1
• A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCLNot yet recruitingNCT06921044Phase 2
• Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell LymphomaRecruitingNCT06919939Phase 2
• Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy FailureRecruitingNCT06918912Phase 2
• Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell LymphomaRecruitingNCT06905509Phase 2
• Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell LymphomaRecruitingNCT06902012Phase 1/2
• Hyperfractionated Dual Equivalent Fractionated Radiation TherapyRecruitingNCT06898905Not applicable
• Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular SubtypesRecruitingNCT06891157Phase 2
• A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)RecruitingNCT06890884Phase 2
• Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCLNot yet recruitingNCT06890585Phase 2
• Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor BurdenRecruitingNCT06867536Phase 2
• Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma SubtypeRecruitingNCT06863402Phase 2
• Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT06859008Phase 1
• Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell LymphomaRecruitingNCT06854445Phase 2
• Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell TherapyRecruitingNCT06854159Phase 2
• CD70-targeted immunoPET Imaging of Malignant CancersRecruitingNCT06852638Phase 2
• Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+RecruitingNCT06846463Phase 2
• Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyRecruitingNCT06834373Phase 2
• Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCLRecruitingNCT06832228Not applicable
• Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular LymphomaRecruitingNCT06830759
• Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell LymphomaRecruitingNCT06829771Phase 1/2
• A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHPRecruitingNCT06828991Phase 2
• Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System LymphomaEnrolling by invitationNCT06827782Phase 1
• Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent LymphomaRecruitingNCT06822829
• Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHLRecruitingNCT06806033Phase 2
• Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLRecruitingNCT06803693Phase 2
• Immunotherapy in LymphomaRecruitingNCT06796517
• Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell TransplantationRecruitingNCT06793410Phase 2
• Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT06792253Phase 3
• Long-term Follow up Local Registry Study of Kymriah in South KoreaRecruitingNCT06785818
• Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-TRecruitingNCT06784726Phase 2
• Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T TreatmentRecruitingNCT06784167
• An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient ProgramRecruitingNCT06782789
• AZA Combined with R-GemOx for Elderly DLBCL PatientsNot yet recruitingNCT06778902Phase 2
• Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma Treated With AnthracyclinesRecruitingNCT06774326
• IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCLRecruitingNCT06768905Phase 1/2
• A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell LymphomaRecruitingNCT06765317Phase 2
• CHiR Therapy for Elderly DLBCL Intolerant to ChemoRecruitingNCT06764017Phase 2
• Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCLRecruitingNCT06760039Phase 1/2
• Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients with DLBCL Intolerant to ChemotherapyRecruitingNCT06758037Phase 2
• PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell LymphomaRecruitingNCT06755775
• Dynamic CtDNA-guided Targeted Therapy in DLBCLNot yet recruitingNCT06748521Phase 2
• Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBLRecruitingNCT06742502Phase 2
• A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell LymphomaRecruitingNCT06736613Phase 2
• The Microbiome in Blood Cancer and HLHNot yet recruitingNCT06734624
• A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)RecruitingNCT06717347Phase 3
• ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCLRecruitingNCT06693830Not applicable
• CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell TransplantRecruitingNCT06687772Phase 2
• A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell LymphomaRecruitingNCT06683885Phase 1/2
• Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCLRecruitingNCT06682130Phase 2
• RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DELRecruitingNCT06674096Phase 2
• Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial RemissionNot yet recruitingNCT06669143Phase 2
• G-Pola-ZLP in Diffuse Large B-Cell LymphomaNot yet recruitingNCT06665217Phase 2
• Pola-ZR2P in Previously Untreated DLBCLRecruitingNCT06664411Phase 2
• The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter StudyNot yet recruitingNCT06656234
• Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor LymphomaNot yet recruitingNCT06652152
• Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC PositiveNot yet recruitingNCT06652139Phase 2
• Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCLRecruitingNCT06651853Phase 2
• Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaRecruitingNCT06649812Phase 2
• Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）RecruitingNCT06647940Phase 2
• Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell LymphomaRecruitingNCT06594939Phase 2
• R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell LymphomaRecruitingNCT06594640Phase 1/2
• Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System InvolvementNot yet recruitingNCT06594432Phase 2
• Autologous Hematopoietic Stem Cell Boost Study After CAR-T TherapyRecruitingNCT06589089Phase 2
• Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell LymphomaRecruitingNCT06588205
• A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCLNot yet recruitingNCT06573645Phase 3
• A Real-World Study on Extranodal LymphomaNot yet recruitingNCT06573099
• A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma PatientsRecruitingNCT06569485Phase 2
• A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT06554600Phase 2
• Emapalumab Prevention of CAR-T Cell Associated ToxicitiesRecruitingNCT06550141Phase 2
• SynKIR-310 for Relapsed/Refractory B-NHLRecruitingNCT06544265Phase 1
• Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaRecruitingNCT06536049Phase 1/2
• Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical StudyRecruitingNCT06534762Phase 2
• Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)RecruitingNCT06533579Phase 1/2
• Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCLRecruitingNCT06530511Phase 2
• Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)RecruitingNCT06526065
• The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaRecruitingNCT06522555Phase 3
• Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT06521255Phase 3
• Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)RecruitingNCT06517511Phase 2
• An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell LymphomaRecruitingNCT06517004Phase 1
• A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLNot yet recruitingNCT06516978Phase 2
• Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCLRecruitingNCT06503263Phase 2
• Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLRecruitingNCT06500273Phase 2
• A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell LymphomaRecruitingNCT06486051Phase 2
• Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell LymphomaRecruitingNCT06464861Phase 1
• Epcoritamab-CAR T Cells for Large B-cell LymphomasRecruitingNCT06458439Phase 2
• This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid TumorsRecruitingNCT06451497Phase 1
• Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLNot yet recruitingNCT06441097Phase 2
• Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow MicroenvironmentRecruitingNCT06439173
• Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)RecruitingNCT06395103Phase 1/2
• A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCLRecruitingNCT06375733Phase 1/2
• Maintenance Hormonal Therapy and DLBCLNot yet recruitingNCT06355401Phase 2/3
• Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?RecruitingNCT06352242Not applicable
• Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPIRecruitingNCT06290817Phase 2
• Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCLNot yet recruitingNCT06289959Not applicable
• Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCLRecruitingNCT06287398Phase 2
• Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell LymphomaRecruitingNCT06249191Phase 1/2

← Lymphoma, Large B-Cell, Diffuse overview